Badreddin Edris Biography and Net Worth

Director and Co-Founder of Edgewise Therapeutics

Badreddin Edris, Ph.D., is a co-founder of Edgewise Therapeutics and serves as a member of our board of directors after having served as our strategic advisor and in an operational role. Dr. Edris is currently the Chief Operating Officer of SpringWorks Therapeutics (NASDAQ: SWTX), a clinical-stage biopharmaceutical company focused on rare diseases and cancer. At SpringWorks, Dr. Edris leads the company’s strategic planning, business development, capital formation, investor relations, and competitive intelligence efforts. Prior to joining SpringWorks, Dr. Edris was an investment and operating professional on the private equity team at OrbiMed where he was involved in deal sourcing, evaluation and execution, as well as post-investment strategic and operational support for biotechnology companies across a range of therapeutic areas and stages of development. In addition to Edgewise, Dr. Edris also co-founded Silverback Therapeutics while at OrbiMed and served as the company’s Chief Business Officer. Before OrbiMed, Dr. Edris was a management consultant at Bain & Company, where he collaborated with global pharmaceutical and biotechnology companies on a range of strategic and operational projects. Dr. Edris received his Ph.D. in genetics from Stanford University School of Medicine, where he was an NSF research fellow.

What is Badreddin Edris' net worth?: The estimated net worth of Badreddin Edris is at least $752.01 thousand as of January 21st, 2026. Dr. Edris owns 19,820 shares of Edgewise Therapeutics stock worth more than $752,010 as of May 5th. This net worth evaluation does not reflect any other investments that Dr. Edris may own. Learn More about Badreddin Edris' net worth.
How do I contact Badreddin Edris?: The corporate mailing address for Dr. Edris and other Edgewise Therapeutics executives is 3415 COLORADO AVE., BOULDER CO, 80303. Edgewise Therapeutics can also be reached via phone at 720-262-7002 and via email at [email protected]. Learn More on Badreddin Edris' contact information.
Has Badreddin Edris been buying or selling shares of Edgewise Therapeutics?: Badreddin Edris has not been actively trading shares of Edgewise Therapeutics in the last ninety days. Most recently, Badreddin Edris sold 115,471 shares of the business's stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $29.44, for a transaction totalling $3,399,466.24. Following the completion of the sale, the director now directly owns 19,820 shares of the company's stock, valued at $583,500.80. Learn More on Badreddin Edris' trading history.
Who are Edgewise Therapeutics' active insiders?: Edgewise Therapeutics' insider roster includes R. Michael Carruthers (CFO), Behrad Derakhshan (Chief Business Officer), Joanne Donovan (CMO), Badreddin Edris (Director and Co-Founder), Jonathan Fox (Director), Kevin Koch (President, CEO and Director), John Moore (General Counsel), Jonathan Root (Director), Alan Russell (Insider), and Peter Thompson (Chairman and Co-Founder). Learn More on Edgewise Therapeutics' active insiders.
Are insiders buying or selling shares of Edgewise Therapeutics?: During the last twelve months, Edgewise Therapeutics insiders bought shares 1 times. They purchased a total of 10,700 shares worth more than $199,448.00. During the last twelve months, insiders at the sold shares 9 times. They sold a total of 360,400 shares worth more than $8,115,350.59. The most recent insider tranaction occured on April, 1st when CMO Joanne M Donovan sold 28,662 shares worth more than $926,069.22. Insiders at Edgewise Therapeutics own 23.2% of the company. Learn More about insider trades at Edgewise Therapeutics.
Information on this page was last updated on 4/1/2026.

Badreddin Edris Insider Trading History at Edgewise Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/21/2026	Sell	115,471	$29.44	$3,399,466.24	19,820

Badreddin Edris Buying and Selling Activity at Edgewise Therapeutics

Edgewise Therapeutics Company Overview

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Today's Range

Now: $38.39

$37.00

$39.96

50 Day Range

MA: $31.11

$27.82

$34.43

2 Week Range

Now: $38.39

$12.15

$39.96

Volume

3,600,198 shs

Average Volume

992,884 shs

Market Capitalization

$4.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.25